Precision Therapeutics Inc has recently expanded its BioSpeciFx product to include 21 clinically relevant biomarkers to help physicians with their treatment decisions. This enhances Precision’s approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test. By utilizing BioSpeciFx results in combination with Precision Therapeutics’ ChemoFx in vitro drug response marker, physicians will receive both molecular and live-cell drug response information about a patient’s tumor. Through the integration of these two tests, physicians can create a comprehensive tumor profile, allowing them to more completely define their patient’s cancer. In an effort to personalize treatment selection even further, BioSpeciFx and ChemoFx tests give physicians the ability to choose from suggested tumor-specific panels or to customize a report for each patient.
"The decision to add new biomarker tests to Precision Therapeutics’ Comprehensive Tumor Profile was a direct result of market trends and customer requests," says Sean McDonald, CEO. "Precision is committed to producing multiple products that help physicians make difficult clinical decisions throughout the cancer care continuum. We are in the process of developing several additional tools to help us adhere to our mission of improving the odds of survival and the quality of life for cancer patients."
Source: Precision Therapeutics
